General introduction
The outcome of any immune response is determined at least in part by the microenvironment in which the response occurs. This microenvironment is in turn determined by a network of short acting cytokines, which may be produced by immunologically active cells and stromal tissue. In view of the critical role these proteins play in regulating immune responses, it is likely that subtle differences in cytokine composition, particularly at the initiation of an immune response, may have a major effect on the outcome of that response. 1 Considerable inter-individual variation exists in cytokine genes (http://www.ncbi.nlm.nih.gov/SNP/index. html, http://www.pam.bris.ac.uk/services/GAI/cytokine 4.htm). While occasional rare mutations may cause catastrophic immune defects, 2 minor changes in nucleotide composition occur very frequently. These changes include single nucleotide polymorphisms (SNPs) in the promoter region of the gene which may influence the rate or extent of cytokine secretion, as may the presence of variable numbers of tandem repeats (VNTRs). Alternatively, coding polymorphisms may affect the structure or biological activity of the encoded cytokine. Many of these common variants have significant biological effects, and the possibility that they influence the heterogeneity of immune responses has led to the rapid expansion of studies examining their role in disease pathogenesis.
The disorders of transplantation are an important paradigm for immunological diseases. Acute cellular rejection is a prototype for delayed type hypersensitivity disorders, while hyperacute rejection is a classic antibody mediated disease. Furthermore, the combination of T cell and humoral events involved in vascular rejection has several features in common with many autoimmune diseases. Thus understanding the role of cytokine polymorphisms in disorders of transplantation has the potential to illuminate the pathogenesis of a variety of infectious and autoimmune disorders. Indeed, the possibility that specific genetic variants may determine the outcome of a transplant has raised the possibility that immunosuppression might be tailored on the basis of recipient or donor genotype. 3 It has been suggested that this would allow better matching of donor and recipient pairs, and identify candidates for clinical trials. 3 However, the importance of this field risks being undermined by nonreplication and even outright refutation of results: unfortunately, early enthusiastic data from some groups, often presented in abstract or lecture form, has frequently not been reproduced. This review summarises the results of relevant peer-reviewed studies, and explores the evidence that cytokine polymorphisms impact upon outcome after solid organ transplantation.
Cytokine polymorphisms and acute rejection
Acute rejection is an important cause of morbidity after transplantation, and the majority of studies determining the impact of cytokine polymorphisms in transplantation have used this as the primary outcome measure. This pathological process is generally orchestrated by activated T lymphocytes and may or may not contain evidence of a T cell driven humoral response. Thus it may be influenced by any cytokine that modulates interactions between T cells and either antigen presenting cells or B cells.
Probably the most widely studied polymorphic cytokine gene is tumour necrosis factor (TNF). TNF is encoded in the Class III region of the major histocompatibility complex (MHC) on chromosome 6. It plays a central role in inflammation and apoptosis, and expression in increased during acute rejection. 4, 5 A number of different TNF polymorphisms have been described, but the majority of transplant-related studies have concentrated on a promoter SNP, TNF −308 (g → a). There is substantial evidence that the presence of an 'a' allele at this position is associated with high TNF production, 6 although this continues to be debated, 7, 8 http://www.pam.bris. ac.uk/services/GAI/cytokine4.htm). On balance, current evidence suggests that the haplotype containing the TNF −308a allele is indeed a high producing haplotype, but it may not be the SNP at position −308 itself that is relevant, 9 and there are undoubtedly other polymorphisms in the TNF gene which significantly influence TNF production. 10 Other polymorphic genes studied in the context of acute rejection include interleukin-10 (IL-10), interferon gamma (IFN␥), interleukin-4 (IL-4), interleukin-6 (IL-6) and transforming growth factor-beta (TGF-␤). The cytokines encoded by these genes are strongly implicated in disease pathogenesis, and differential expression during rejection has been demonstrated. [11] [12] [13] A promoter polymorphism at position −1082 in the IL-10 promoter has been particularly widely studied, as it has been shown to influence cytokine production.
14 Amongst other effects IL-10 has profound anti-inflammatory activity. 15 As IL-10 may directly oppose the action of pro-inflammatory cytokines such as TNF, this suggests that IL-10 and TNF polymorphisms may synergise in vivo to determine the local inflammatory milieu.
Recipient polymorphisms and acute rejection:
The impact of recipient TNF −308 genotype on acute rejection has now been examined in over a thousand recipients of solid organ transplants (Table 1 ). In general, no direct association with incidence or severity of acute rejection has been documented, [16] [17] [18] [19] [20] [21] although in one study of liver transplant recipients, homozygosity for the −308a allele was weakly associated with rejection. 22 However, the presence of the TNF −308a allele has been associated with multiple rejection episodes, including kidney and kidneypancreas transplant recipients, 19 pediatric heart recipients, 23 and in a subgroup of HLA-DR mismatched renal transplant recipients, 24 although this has not been a universal finding. 21 Thus while this remains a promising area of interest, there is currently no consistent evidence to support the premise that TNF genotype has a significant independent impact on acute rejection after transplantation.
The IL-10 −1082 polymorphism has also been widely studied. Again, this SNP has not been independently associated with acute rejection 16, [18] [19] [20] [21] [22] 24, 25 with the exception of one small study of pediatric heart transplant recipients. 23 Nonetheless, considerable attention has focused on the effect of the combinations of IL-10 and TNF genotypes: in the initial study of cytokine polymorphisms in transplant recipients, a post-hoc analysis showed that individuals who carried both a TNF −308a allele (termed in some studies the 'high producing' allele) and the IL-10 genotype −1082a/a (the 'low producing' genotype) were at high risk of repeated acute rejection in the first 3 months after cardiac transplantation. 16 While numbers were small, the plausibility of this in vivo interaction made this a very interesting finding. However this synergy has not been confirmed in subsequent studies: on the contrary, in renal transplant recipients one study has demonstrated an association between TNF −308a and the 'high producing' IL-10 −1082g/g genotype with multiple acute rejection episodes, 24 while another also found an association of recurrent rejection with the 'high producing' IL-10 −1082g/g genotype but only in individuals who did not also carry the TNF −308a allele. 19 Three additional studies, two in renal transplantation and one in liver transplantation, found no combined effect of TNF and IL-10 genotype. 18, 21, 22 A variety of other recipient polymorphic cytokines have been studied, but no significant associations have been identified between acute rejection and recipient TGF␤ polymorphisms, [18] [19] [20] [21] [22] [23] IFN␥ polymorphisms, 20, 23, 26 IL-6 polymorphisms 18, 20, 23 or IL-1RA and IL-1␤ polymorphisms. 18, 27 Donor polymorphisms and acute rejection: During host-graft interactions, the immunological milieu is not only influenced by recipient cytokines but also by cytokines derived from the donor, whether produced by donor antigen presenting cells or by stromal tissue. While this has not been widely studied, two associations with cytokine polymorphisms have been described. Firstly, a highly significant association between donor IL-6 promoter genotype (IL-6 −174c/c) and acute rejection has been identified in a large cohort of renal transplant donors. 28 This association was particularly strong with steroid-unresponsive acute rejection and was evidenced in both HLA-DR matched and mismatched kidneys. While this finding requires confirmation, a clue as to the mechanism by which this polymorphism exerts its effect may be its location near two steroid response elements, 29 which may influence response to immunosuppressive therapy. The second donor association is with IL-4 promoter polymorphisms and acute rejection. This has been studied in two renal transplant cohorts, 21, 28 and was found to be significantly associated in one.
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Cytokine polymorphisms and chronic allograft failure Chronic allograft failure (CAF) remains the major single cause of graft loss after solid organ transplantation. The pathogenesis of CAF appears to be mediated by a combination of immunological, inflammatory and atherogenic factors. Cytokines such as TGF-␤ which are involved in both lymphocyte regulation and endothelial repair are therefore excellent candidates for involvement. Indeed, increases or decreases in the production of TGF-␤ have been linked to numerous native disease states, including atherosclerosis and fibrotic disease of the kidney, liver, and lung. 30 Production of TGF-␤ is genetically regulated, 31 and is determined in part by polymorphisms in the TGFB1 gene. These include two SNPs in the gene promoter (TGFB1 −800 and −509) and two in the signal sequence (TGFB1 amino acid 10 and amino acid 25). 32 Both the −509t/c polymorphism and the amino acid 25 polymorphism have been associated with variation in serum levels of TGF-␤. 31, 33 A number of studies of TGF-␤1 polymorphisms and CAF have now been reported. The most consistent finding has been the association of homozygosity for arginine at amino acid 25 (aa25R/R) with CAF or fibrotic disease in lung 33 and heart 34, 35 transplant cohorts. However the largest study to date showed no effect of this polymorphism, but rather an association with recipient codon 10P/P genotype after multivariate analysis. 36 
Cytokine polymorphisms and graft survival
The majority of studies have examined clinical parameters such as acute rejection as major end points, but an alternative approach has been to correlate cytokine polymorphisms with graft survival. Hackstein et al demonstrated that an IL-4 receptor variant known to influence signal transduction (Q576R 37 ) was associated with poor long-term graft survival after renal transplantation. 38 This polymorphism has not been widely studied in association with either acute rejection or chronic allograft failure, and it is not clear how its effect may be mediated.
Discussion
How important are cytokine polymorphisms in determining outcome after solid organ transplantation? Can cytokine genotyping deliver the dream of individualised immunosuppression? Our opinion is that at present there is no unequivocal evidence that cytokine polymorphisms determine either acute rejection or chronic allograft failure sufficient to change clinical practice. Indeed, the major feature of the results of these studies is their highly discrepant findings. This is likely to be the result of a large number of different factors. Firstly, it is possible that the variability of results reflect heterogeneity of disease pathogenesis. For example, individual cytokines may play divergent roles depending on the organ transplanted, and thus comparison across different solid organ transplants may be inappropriate. However, conflicting results have emerged even between very similar patient cohorts, suggesting that additional factors are also involved. An alternative explanation is that the importance of a single cytokine polymorphism is very dependent upon the type of immunosuppression used. For example, the significance of polymorphisms which influence TNF production may be greater in patients treated with cyclosporine monotherapy than those maintained on a regimen which includes corticosteroids, because of the inhibitory effect of corticosteroids on TNF synthesis. This could not only give rise to problems when comparing results from different studies, but may also confound individual studies if patients are maintained on different immunosuppressive regimens. Further complexity may result from the use of different inclusion criteria and disease definition in different studies, such as the requirement for histological confirmation of acute rejection, and accurate and consistent clinical definition is paramount for all genetic studies of multifactorial diseases.
An additional complicating factor of these studies is that the in vivo effect of many of these polymorphisms remains highly controversial (http://www.pam.bris. ac.uk/services/GAI/cytokine4.htm). Differences in in vitro and in vivo activity may result from a number of factors, both technical (such as differences in assay format), or genetic (such as the effect of other polymorphisms in linkage disequilibrium). We would therefore strongly suggest that analysis of polymorphisms according to presumed in vivo phenotype ('high', 'intermediate', and 'low' phenotype) is premature, and obscures rather than illuminates a highly complex area.
Finally, determining the impact of genetic factors after transplantation inevitably requires case-control study design, due to a low poplation incidence and a lack of suitable families. While studies with appropriatedly matched cases and controls are a highly efficient means for detecting associations, they are inherently prone to a number of problems. These include small numbers, inadequacy of the control group, population stratification, multiple hypothesis testing, over interpretation of results, and inadequate statistical methods. 39, 40 Furthermore, the inherent bias of publication means that even well designed studies with negative results are less likely to be published than positive ones. Indeed, it is sobering to remember that the majority of disease association studies are never replicated, 41 and the diseases of solid organ transplantation appear to be no exception.
Nonetheless, transplanters have previously overcome very similar problems: after initial controversy and debate, there is now unequivocal evidence of the influence of HLA compatibility on graft outcome. 42, 43 This has been demonstrated despite differences in ethnicity, original disease, rejection definition and post-transplant immunosuppression, through the use of national and international databases.
The introduction of a cytokine polymorphism component to the framework of the 13th international histocompatibility working group (IHWG) is an exciting development (http://www.ihwg.org/components/cytokine/ cytover.htm). This project will study the genomic variability that characterises genes encoding 15 designated cytokines (IL-1␣; IL-1␤; IL-1R; IL-1RA, IL-2; IL-4; IL-4R; IL-6; IL-10; IL-13; IL-15; TGF␤1; TNF; TOL-R; and IFN␥). After initial assessment of typing methodologies, a standard set of reagents will be distributed to all participants for independent studies on transplant and other patient cohorts. It is planned that the results will be reported to a central database, in addition to being analysed by individual groups. Thus this workshop may herald the beginning of new collaborative databases along the lines of those held by United Network for Organ Sharing (UNOS) and the Collaborative Transplant Study. It is likely that only with this data will we be able to conclusively demonstrate if cytokine polymorphisms play a role in determining transplant outcome.
